Clinical Trials
6 trialsNCT04649359 2026-05-19
MagnetisMM-3: Study Of Elranatamab (PF-06863135) Monotherapy in Participants With Multiple Myeloma Who Are Refractory to at Least One PI, One IMiD and One Anti-CD38 mAb
Pfizer
Phase 2 Active not recruiting
NCT02952508 2026-03-18
CLOVER-WaM
Cellectar Biosciences, Inc.
Phase 2 Active not recruiting
NCT04155749 2026-02-11
Study of Anitocabtagene-autoleucel in Participants With Relapsed Refractory Multiple Myeloma
Gilead Sciences
Phase 1 Active not recruiting
NCT03162536 2025-09-08
ARQ 531-101
ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
Phase 1/2 Active not recruiting
NCT02899052 2025-08-05
Study of Venetoclax in Combination With Carfilzomib and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma (MM)
AbbVie
Phase 2 Active not recruiting
NCT04782687 2025-01-16
Study of Selinexor Plus DRd for Newly Diagnosed Multiple Myeloma
US Oncology Research
Phase 2 Active not recruiting